Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium

@article{Mrmol2008LithiumBD,  title={Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium},  author={Frederic M{\'a}rmol},  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},  year={2008},  volume={32},  pages={1761-1771},  url={https://api.semanticscholar.org/CorpusID:25861243}}

177 Citations

Potential Mechanisms of Action of Lithium in Bipolar Disorder

It is clear that the processes which underpin the therapeutic actions of lithium are sophisticated and most likely inter-related.

Lithium in the Treatment of Bipolar Disorder: Evidence of Intracellular Mechanisms that Substantiate Two Prominent Theories of Action

The data is reviewed in support of two prominent theories that point to Gsk-3 inhibition and inositol depletion as molecular targets with respect to hippocampal structures and Examination of their intracellular mechanisms provides targets for novel pharmacotherapies in the treatment of Bipolar Disorder.

The role of lithium in modulation of brain genes: relevance for aetiology and treatment of bipolar disorder.

A number of genes associated with bipolar disorder, including Comt (catechol-O-methyltransferase), Vapa (vesicle-associated membrane protein-associated protein A), Dtnb (dystrobrevin beta) and Pkd1 (polycystic kidney disease 1), were significantly altered in the microarray dataset along with genes associatedwith synaptic transmission, apoptosis and transport among other functions.

Lithium: Neurotransmission and Cellular Mechanism Pathways Underlying Neuroprogression in Bipolar Disorder

This chapter reviews the therapeutic effects of lithium on neurotransmission and cellular signal transduction mechanisms underlying neuroprogression in bipolar disorder and key glycogen synthase kinase-3β-mediated mechanisms are highlighted, as they appear pivotal to therapeutic response.

Bipolar Disorders and Lithium: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Indications of Lithium: Review of Articles

    Medicine
  • 2016
Lithium is a mood stabilizer which is approved for use in acute and maintenance mania. It is the first medications approved for the treatment of bipolar disorders. The drug has narrow therapeutic…

Lithium: a key to the genetics of bipolar disorder

Evidence suggests that individuals who respond well to lithium treatment have more homogeneous clinical and molecular profiles, and response to lithium seems to cluster in families and can be used as a predictor for recurrence of BD symptoms.

Beyond its Psychiatric Use: The Benefits of Low-dose Lithium Supplementation

A review of low-dose lithium's potential benefits on the aging process and age-related diseases of these systems, such as cardiovascular disease, osteoporosis, sarcopenia, obesity and type 2 diabetes, Alzheimer’s disease, and the chronic low-grade inflammatory state known as inflammaging is summarized.

Lithium: the pharmacodynamic actions of the amazing ion

Support is provided for a role for the inhibition of glycogen synthase kinase 3 and inositol monophosphatase in the pharmacodynamic actions of lithium, and how inhibition of these enzymes by lithium can lead to downstream effects of clinical relevance, both for mood disorders and neurodegenerative diseases.
...

190 References

Molecular effects of lithium.

Recent insights into lithium's actions are reviewed, leading to the strategic development of improved therapeutics for the treatment of bipolar disorder and its intracellular downstream targets including adenylate cyclase, the phosphoinositol cascade, arachidonic acid metabolism, and effects on neurotrophic cascade.

Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

The task of developing novel medications for bipolar disorder is truly daunting, and it is hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.

The nature of bipolar disorder.

Regulation of gene expression and identification of factors regulating neuroplasticity and neurotrophic events in the central nervous system in bipolar disorder are 2 of the more recent approaches contributing to clarification of the pathophysiology and potential treatment options.

Endophenotypes in bipolar disorder.

Findings in patients with bipolar disorder that may eventually be useful as endophenotypes include abnormal regulation of circadian rhythms, response to sleep deprivation, P300 event-related potentials, behavioral responses to psychostimulants and other medications, Response to cholinergics, increase in white matter hyperintensities, and biochemical observations in peripheral mononuclear cells.

No association between the PREP gene and lithium responsive bipolar disorder

The findings do not support the hypothesis that genetic variation in this gene plays a major role in the etiology of BD or Li response, and PREP is an interesting candidate gene to investigate in genetic studies of BD.

A common mechanism of action for three mood-stabilizing drugs

It is shown that all three lithium, carbamazepine and valproic acid drugs inhibit the collapse of sensory neuron growth cones and increase growth cone area, suggesting a molecular basis for both bipolar affective disorder and its treatment.
...

Related Papers

Showing 1 through 3 of 0 Related Papers